Biohaven licenses Hangzhou Highlightll’s BHV-8000 to treat brain disorders
Pharmaceutical Technology
MARCH 23, 2023
The deal gives Biohaven global rights for the development of BHV-8000, excluding regions of China. BHV-8000’s mechanistic proof of concept was showed in several pre-clinical models. This year, Biohaven is expecting to advance the TYK2/JAK1 inhibitor into a Phase I trial.
Let's personalize your content